SEC Tracker
Get the app

TransMedics Group TMDX

TransMedics Group Q1 FY24: revenue $96.8M; diluted EPS $0.35

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers TransMedics Group reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$96.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income$12.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS$0.35No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$350.2MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$3.4MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when TransMedics Group files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.

  1. Integer Holdings ITGR public float $4.3B, Jun 27, 2025
  2. iRhythm Holdings IRTC public float $4.9B, Jun 30, 2025
  3. Masimo MASI public float $3.9B, Jun 28, 2025
  4. Inspire Medical Systems INSP public float $3.8B, Jun 30, 2025
  5. Merit Medical Systems MMSI public float $5.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.